A Phase 2 interventional study of Nicotinamide Riboside (NR) and Placebo in Frailty, Frail Elderly Syndrome and Frailty Syndrome, sponsored by Haukeland University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2025-01-20.
Sponsored by Haukeland University Hospital · Phase 2, Interventional, and Treatment
This clinical study, designed as a double-blind, randomized, placebo-controlled trial, aims to investigate the potential of nicotinamide riboside (NR) to decelerate functional decline in the elderly frail population. In animal studies, NR, which is converted to nicotinamide adenine dinucleotide (NAD), has shown potential as a neuroprotective agent, with indications of protection against amyotrophic lateral sclerosis (ALS), Alzheimer's dementia, and Parkinson's disease. Furthermore, aging is commonly associated with decreased tissue NAD levels, a phenomenon linked to premature aging and a spectrum of age-related disorders, including cardiovascular diseases and cancers. Existing preclinical and clinical research highlights the promise of NAD replenishment through enhanced DNA repair, sirtuin activity, and improved mitochondrial function. The research center has conducted two phase II clinical trials on NR for Parkinson's disease (NAD-PARK and NR-SAFE), administering up to 3000 mg of NR daily. These trials have shown promising results, indicating NR's potential as a treatment that may alter the course of the disease and possibly as neuroprotective treatment in Parkinson's disease.
The NAD age trial primarily aims to determine:
The study will include 100 individuals, classified as frail based on the Fried Frailty Phenotype. Participants will be randomly assigned to receive either 2000 mg of NR daily or a placebo. Over a 52-week period, participants will undergo:
The outcomes of this study could potentially demonstrate that NR effectively reduces signs of frailty, offering considerable advantages to the individuals affected, their families, and society as a whole.
This study aims to administer 2000 mg of nicotinamide riboside (NR) daily to explore its effects on brain and body metabolism in an elderly, frail population. The research design is a single-center, double-blind, randomized, placebo-controlled approach. Participants will be evenly randomized into two groups in a 1:1 ratio: one to receive a placebo and the other to receive 2000 mg of NR daily. The intervention will last for 52 weeks, during which primary and secondary outcomes will be assessed across and within both groups.
The primary objective is to evaluate the impact of NR on gait speed by comparing the treatment group with the placebo group. Secondary objectives include assessing the safety and tolerability of NR, as well as its clinical effects on physical and cognitive functions, using standardized tests. Furthermore, exploratory objectives will be pursued using various methods such as questionnaires, biosampling, actigraphy, and brain scans. These scans will include 31P-MR-spectrometry to analyze NAD levels in the brain and FDG-PET to assess metabolic network activity. The study will include 100 frail individuals who have provided informed consent. Biological samples to be collected include blood/serum, blood cells, urine, and fecal samples.
Given the previously demonstrated potential of NR in reducing symptoms of Parkinson's disease, this study seeks to expand knowledge of its effects on an elderly, frail population without neurodegenerative disorders. If NR is found to be effective in improving measures of frailty, it could significantly impact societal health and economy, especially considering the extensive socio-economic challenges associated with frailty.
9,217 studies on the registry are indexed under Syndrome; 1,031 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 6,515 interventional studies indexed under Syndrome.
Browse Syndrome studies →Haukeland University Hospital is the lead sponsor of 276 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (1 year).
Other: Placebo
Nicotinamide Riboside (NR) administered in doses of 1000 mg twice daily for the duration of the trial (1 year).
Dietary Supplement: Nicotinamide Riboside (NR)
A total of 2000 mg NR is administered daily for 1 year.
Placebo tablet identical in taste, shape and appearance to NR tablets.
The between-group (NR vs. Placebo) difference in the change in gait speed.
Gait speed is assessed by the 6-minute walk test (6MWT).
Time frame: 52 weeks
Incidence of treatment-emergent adverse events (safety and tolerability).
Monitor the frequency and severity of adverse events (AE).
Time frame: 52 weeks
Change in physical performance assessed by the Short Physical Performance Battery (SPPB).
SPPB is performed as an objective measurements on balance, lower extremity strength, and functional capacity through walking and sit to stand test.
Time frame: 52 weeks
Change in physical performance assessed by hand grip strength.
Grip strength is measured on the dominant hand with a hydraulic hand-held dynamometer.
Time frame: 52 weeks
Change in cognitive function assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) test battery.
The RBANS test battery is composed of tests on immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory. Score range: 40-160. A higher score indicates a better performance.
Time frame: 52 weeks
Change in daily step count.
Measured in number of steps using Axivity wearable sensors. Counts the total number of steps taken by an individual over a specified period.
Time frame: 52 weeks
Change in overall activity level.
Measured in activity counts using Axivity's accelerometer data. Quantifies the total amount of physical activity based on intensity and duration.
Time frame: 52 weeks
Change in speed of movements.
Measured in per second (m/s) using Axivity's accelerometer and gyroscope data. Calculates the average or peak speed of movements during different activities.
Time frame: 52 weeks
Change in acceleration of movements.
Measured in meters per second squared (m/s2) using Axivity's accelerometer data. Measures the rate of change of speed, indicating how quickly an individual is increasing or decreasing speed during activities. Measured in meters per second squared (m/s\^2) using Axivity's accelerometer data.
Time frame: 52 weeks
Change in angular velocity of movements.
Measured in radians per second (rad/s) using Axivity's gyroscope data. Measures the rate of rotation around an axis, assessing movement dynamics.
Time frame: 52 weeks
Change in Activities of Daily Living (ADL) score.
Assessed by the Barthel Index Activities of Daily Living (ADL) scale. Score range: 0 - 20. A higher score indicate better functional status.
Time frame: 52 weeks
Change in Independent living skills (IADL) score.
Assessed by the Nottingham Instrumental Activities of Daily Living (IADL) scale. Score range: 0-66. A higher score indicate better functional status.
Time frame: 52 weeks
Change in mobility assessed by the Life Space Questionnaire (LSQ).
Score range: 0-18. A higher score indicates more limited mobility.
Time frame: 52 weeks
Change in mood assessed by the Montgomery Aasberg Depression Rating Scale (MADRS).
Score range: 0-54. Higher score indicates a greater severity of depressive symptoms.
Time frame: 52 weeks
Change in self-reported mood assessed by the Geriatric depression scale (GDS).
Score range: 0-30. A higher score indicates more severe depressive symptoms.
Time frame: 52 weeks
Change in self-assessment of perceived health assessed by the Short form 36 (RAND-36).
The RAND-36 assessment does not provide a single summary score; rather, it offers scores for each of eight domains (physical functioning, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, pain, and general health perceptions), allowing for a comprehensive assessment of a person's health-related quality of life.
Time frame: 52 weeks
Change in sleep assessed by the Pittsburgh Sleep Quality Index (PSQI) global score.
Seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicates worse sleep quality.
Time frame: 52 weeks
Change in smell identification capacity assessed using the Brief Smell Identification Test (BSIT).
Score range: 0-12. A higher score indicates better smell identification.
Time frame: 52 weeks
Change in nutritional status assessed using the Mini Nutritional Assessment (MNA) form.
Score range: 0-30. A higher score indicates better nutritional status.
Time frame: 52 weeks
Change in sarcopenia assessment.
Assessed using anthropometric measures (weight and height will be combined to report BMI in kg/m\^2).
Time frame: 52 weeks
Change in health-related quality of life assessed by a standardized measure of quality of life (the EQ-5D-5L questionnaire).
The EQ-5D-5L does not provide a single summary score; rather, it offers three levels, where level 1 indicates higher quality of life.
Time frame: 52 weeks
Change in cognitive function using the Grooved Pegboard test.
Test on motor function, attention, and executive functioning.
Time frame: 52 weeks
Change in cumulative illness / comorbidity examined using the Cumulative Illness Rating Scale-Geriatric (CIRS-G).
CIRS-G does not provide a single summary score; rather, it offers four levels of severity where level 4 is the highest severity of comorbidity.
Time frame: 52 weeks
Change in social support assessed using the Multidimensional scale of perceived social support (MSPSS).
Score range: 12-84. Higher scores indicates higher perceived support.
Time frame: 52 weeks
The between-visit difference in cerebral NAD levels.
Measured by 31P-Magnetic resonance spectroscopy (31P-MRS)
Time frame: 52 weeks
The between-visit difference in expression of the Nicotinamide Riboside Related Pattern (NRRP).
Measured by fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PET).
Time frame: 52 weeks
The between-visit difference in levels of NAD-metabolites in whole blood.
Measured by liquid chromatography-mass spectrometry (LC-MS).
Time frame: 52 weeks
Change in blood-based biomarkers.
Blood routine biochemistry encompassing cardiovascular-, metabolic-, renal- and hepatic markers, immune- and inflammatory profiles.
Time frame: 52 weeks
Change in gene and protein expression levels related to lysosomal and proteasomal function.
The between-visit change in gene and protein expression levels related to lysosomal and proteasomal function in whole blood, measured by RNA sequencing (RNAseq) and proteomics (LC-MS), respectively.
Time frame: 52 weeks
Change in genomic distribution of DNA methylation.
The between-visit difference in genomic distribution of DNA methylation, measured by the Illumina Infinium MethylationEPIC Kit.
Time frame: 52 weeks
Change in levels of DNA methylation.
The between-visit difference in levels of DNA methylation, measured by the Illumina Infinium MethylationEPIC Kit.
Time frame: 52 weeks
Change in gut microbiome composition.
The between-visit difference in gut microbiome composition, assessed by metagenomics in fecal samples.
Time frame: 52 weeks
Change in fecal metabolomics.
The between-visit difference in fecal metabolomics, including fatty acid profiling.
Time frame: 52 weeks
Change in levels of inflammatory cytokines in serum.
The between-visit difference in levels of inflammatory cytokines in serum measured using the ELISA method.
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haukeland University Hospital